Francisco Escamilla-Sevilla

Francisco Escamilla-Sevilla

Auto-generated profile, based on publicly available information

Francisco Escamilla-Sevilla

Movement Disorders Unit, Neurology Service, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria Ibs.GRANADA, Granada, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
MNMike A Nalls
Mike A Nalls
CBCornelis Blauwendraat
Cornelis Blauwendraat
KHKarl Heilbron
Karl Heilbron
SBSara Bandres-Ciga
Sara Bandres-Ciga
DCDiana Chang
Diana Chang
FZFutao Zhang
Futao Zhang

5 June 2007 in Neurology
Verified
Journal Article
Closed access
PDF file
AMAdolfo Mínguez-Castellanos
Adolfo Mínguez-Castellanos
CCC. E. Chamorro
C. E. Chamorro
FEF. Escamilla-Sevilla
F. Escamilla-Sevilla
AOA. Ortega-Moreno
A. Ortega-Moreno
ARA. C. Rebollo
A. C. Rebollo
DMDavid G Munoz
David G Munoz
Objective: To determine the prevalence of α-synuclein (AS) aggregates in abdominopelvic autonomic plexuses in the general population and to evaluate the relationship between this finding and the subsequent development of neurologic dysfunction. Methods: First, surgical specimens from 100 patients (ages 44 to 84) undergoing a wide resection of an abdominopelvic organ were examined by anti-AS immunostaining. Second, 16 patients (6 AS+ and 10 randomly selected AS−) participated in yearly double-blinded neurologic assessments. Results: AS aggregates were found in autonomic plexuses in 9% of the whole sample (95% CI 3.4 to 14.6%) but were more common in vesicoprostatic (26%) than in digestive tract (4%) specimens. At 16 months after the biopsy, no prevalent cases of Parkinson disease, dementia, or autonomic failure were diagnosed among participants. One AS+ patient had previously been diagnosed with REM sleep behavior disorder. Seven of 10 control subjects but none of the 6 AS+ patients had a diagnosis of hypertension (p = 0.01). During phase IV of Valsalva maneuver, AS+ group exhibited a longer blood pressure recovery time (p = 0.03), with one patient showing absence of blood pressure overshoot. Cardiac [123I]metaiodobenzylguanidine uptake was reduced in the AS+ group (p = 0.03). Striatal [123I]ioflupane uptake was abnormally low in only one AS+ patient. At 30 months after the biopsy, lower cardiac and striatal uptake values tended to correlate with higher Unified Parkinson9s Disease Rating Scale III scores (p = 0.07). Conclusion: The common presence of α-synuclein aggregates in peripheral autonomic neurons may represent an early presymptomatic phase in the development of Lewy body disorders.

1 August 2007 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
AMAdolfo Mínguez-Castellanos
Adolfo Mínguez-Castellanos
FEFrancisco Escamilla-Sevilla
Francisco Escamilla-Sevilla
GHGary R Hotton
Gary R Hotton
JTJuan J Toledo-Aral
Juan J Toledo-Aral
ÁOÁngel Ortega-Moreno
Ángel Ortega-Moreno
JLJosé López-Barneo
José López-Barneo
Background: Carotid body (CB) glomus cells are highly dopaminergic and express the glial cell line derived neurotrophic factor. The intrastriatal grafting of CB cell aggregates exerts neurotrophic actions on nigrostriatal neurons in animal models of Parkinson disease (PD). Objective: We conducted a phase I–II clinical study to assess the feasibility, long term safety, clinical and neurochemical effects of intrastriatal CB autotransplantation in patients with PD. Methods: Thirteen patients with advanced PD underwent bilateral stereotactic implantation of CB cell aggregates into the striatum. They were assessed before surgery and up to 1–3 years after surgery according to CAPIT (Core Assessment Programme for Intracerebral Transplantation) and CAPSIT-PD (Core Assessment Programme for Surgical Interventional Therapies in Parkinson’s Disease) protocols. The primary outcome measure was the change in video blinded Unified Parkinson’s Disease Rating Scale III score in the off-medication state. Seven patients had 18F-dopa positron emission tomography scans before and 1 year after transplantation. Results: Clinical amelioration in the primary outcome measure was observed in 10 of 12 blindly analysed patients, which was maximal at 6–12 months after transplantation (5–74%). Overall, mean improvement at 6 months was 23%. In the long term (3 years), 3 of 6 patients still maintained improvement (15–48%). None of the patients developed off-period dyskinesias. The main predictive factors for motor improvement were the histological integrity of the CB and a milder disease severity. We observed a non-significant 5% increase in mean putaminal 18F-dopa uptake but there was an inverse relationship between clinical amelioration and annual decline in putaminal 18F-dopa uptake (r = −0.829; p = 0.042). Conclusions: CB autotransplantation may induce clinical effects in patients with advanced PD which seem partly related to the biological properties of the implanted glomus cells.

1 August 2003 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
VAVentura Arjona
Ventura Arjona
AMAdolfo Mínguez-Castellanos
Adolfo Mínguez-Castellanos
RMRafael J. Montoro
Rafael J. Montoro
AOAngel Ortega
Angel Ortega
FEFrancisco Escamilla
Francisco Escamilla
JLJosé López-Barneo
José López-Barneo
OBJECTIVE. In this study, we assessed the feasibility of autotransplantation of carotid body (CB) cell aggregates into the striatum for the treatment of

29 October 2019 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
SCSARA bandres ciga
SARA bandres ciga
SASarah Ahmed
Sarah Ahmed
MSMarya S. Sabir
Marya S. Sabir
CBCornelis Blauwendraat
Cornelis Blauwendraat
AAAstrid D. Adarmes‐Gómez
Astrid D. Adarmes‐Gómez
OCon behalf of the International Parkinson Disease Genomics Consortium
on behalf of the International Parkinson Disease Genomics Consortium

26 March 2018 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
CNCarlos Javier Madrid Navarro
Carlos Javier Madrid Navarro
FEFrancisco Escamilla-Sevilla
Francisco Escamilla-Sevilla
AMAdolfo Mínguez-Castellanos
Adolfo Mínguez-Castellanos
MCManuel Campos
Manuel Campos
FRFernando Ruiz-Abellán
Fernando Ruiz-Abellán
MRM. A. Rol
M. A. Rol
Parkinson’s disease (PD) is associated with several non-motor symptoms that may precede the diagnosis and constitute a major source of frailty in this population. The digital era in health care has open up new prospects to move forward from the qualitative and subjective scoring for PD with the use of new wearable biosensors that enable frequent quantitative, reliable, repeatable, and multidimensional measurements to be made with minimal discomfort and inconvenience for patients. A cross-sectional study was conducted to test a wrist-worn device combined with machine-learning processing to detect circadian rhythms of sleep, motor, and autonomic disruption, which can be suitable for the objective and non-invasive evaluation of PD patients. Wrist skin temperature, motor acceleration, time in movement, hand position, light exposure, and sleep rhythms were continuously measured in 12 PD patients and 12 age-matched healthy controls for seven consecutive days using an ambulatory circadian monitoring device (ACM). Our study demonstrates that a multichannel ACM device collects reliable and complementary information from motor (acceleration and time in movement) and common non-motor (sleep and skin temperature rhythms) features frequently disrupted in PD. Acceleration during the daytime (as indicative of motor impairment), time in movement during sleep (representative of fragmented sleep) and their ratio (A/T) are the best indexes to objectively characterize the most common symptoms of PD, allowing for a reliable and easy scoring method to evaluate patients. Chronodisruption score, measured by the integrative algorithm known as the circadian function index is directly linked to a low A/T score. Our work attempts to implement innovative technologies based on wearable, multisensor, objective, and easy-to-use devices, to quantify PD circadian rhythms in huge populations over extended periods of time, while controlling at the same time exposure to exogenous circadian synchronizers.